French Guiana Wellness Network: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.

Press releases published on September 30, 2026

Sep. 30, 2026

CURE ALZHEIMER’S FUND AWARDS $6.4 MILLION TO CARDINAL FAMILY SCHOLARS ADVANCING ALZHEIMER’S RESEARCH

Indeterminate GlobeNewswire

Sep. 30, 2026

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

Indeterminate GlobeNewswire

Sep. 30, 2026

Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings

Indeterminate GlobeNewswire

Sep. 30, 2026

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Indeterminate GlobeNewswire

Sep. 30, 2026

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Indeterminate GlobeNewswire

Sep. 30, 2026

Ocugen to Participate in Upcoming Scientific Conferences

Indeterminate GlobeNewswire

Sep. 30, 2026

R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia

Indeterminate GlobeNewswire

Sep. 30, 2026

EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application

Indeterminate GlobeNewswire

Sep. 30, 2026

More Than 1,600 Participants Anchor Calroy Health Sciences' Joint Formulation Research

Indeterminate GlobeNewswire

Sep. 30, 2026

Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

Indeterminate GlobeNewswire

Sep. 30, 2026

Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate Phase 3 Clinical Trial of Sovateltide in Traumatic Brain Injury

Indeterminate GlobeNewswire

Sep. 30, 2026

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

Indeterminate GlobeNewswire

Sep. 30, 2026

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Indeterminate GlobeNewswire

Sep. 30, 2026

10 Barrel Expands Salty Sips RTD Portfolio with New Blackberry Refresher

Indeterminate GlobeNewswire

Sep. 30, 2026

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

Indeterminate GlobeNewswire

Sep. 30, 2026

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

Indeterminate GlobeNewswire

Sep. 30, 2026

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

Indeterminate GlobeNewswire

Sep. 30, 2026

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

Indeterminate GlobeNewswire

Sep. 30, 2026

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Indeterminate GlobeNewswire

Sep. 30, 2026

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

Indeterminate GlobeNewswire